news
Drug approval harmonisation shows savings potential
Researchers have compared the regulatory authorities responsible for approving drugs and medical products to verify their effectiveness and safety...
List view / Grid view
Biosimilars
article
Risky endeavours for biosimilars market
Bringing a biosimilar from early development to market is a risky endeavour say Magnus Franzen (left) and Chris Isler, biosimilar experts at PA Consulting Group...
news
BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
news
UK trails behind EU in cancer diagnosis & treatment
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
news
Sandoz receives EU approval in Europe for Rixathon (biosimilar rituximab)
The EC has approved Sandoz’ Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine...
news
AAM praises Supreme Court Ruling granting access to biosimilars
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
whitepaper
Whitepaper: Antibody capture and analysis
The development and production of antibody biopharmaceuticals and biosimilars require specific chromatographic tools for efficient purification and QC analysis to improve process economics, safety, and time-to-market.
news
Biosimilar trastuzumab candidate shown similar in efficacy and safety
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
news
New EMA guidelines on biosimilar medicines
1 June 2017 | By Niamh Marriott, Junior Editor
The European Medicines Agency (EMA) and the European Commission have published an information guide for healthcare professionals on biosimilar medicines...
article
Why biosimilars are changing the pharmaceutical industry
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
news
Biosimilar medicines: Dramatic increase in patient access across Europe
23 May 2017 | By Niamh Marriott, Junior Editor
Biosimilar medicines have dramatically increased patient access to biological medicines, according to the recently published QuintilesIMS report...
article
Biosimilars: the future of Pharma? An interview with Boehringer Ingelheim
3 May 2017 | By Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim
With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…
news
Sandoz proposed biosimilars recommended for EU approval
25 April 2017 | By Niamh Marriott, Junior Editor
The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.
news
Global trade bodies issue guidance on biosimilar switching
9 March 2017 | By European Pharmaceutical Review
EFPIA, EBE and IFPMA issue joint guidance for prescribers on switching between original reference biologics and biosimilars...
article
Biosimilars create opportunities for sustainable cancer care
22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group
Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...
